Company intelligence / Profile preview

Accelyon

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~312
Development stage: Other

Overview

Acceleron's lead programs include REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent approved in the US, Europe, Canada, and Australia for anemia in rare blood disorders[5], and sotatercept, which completed Phase 3 trials for pulmonary arterial hypertension[1][5].

Therapeutic areas: HematologyCardiovascularNeurologyOncology
Modalities: Recombinant fusion protein
Industry: Biotech

Partnerships

Bristol Myers Squibb (global collaboration for luspatercept development and commercialization)Celgene (partnership for ACE-011 and ACE-536 development, 2008-2011)

Beyond the preview

Go deeper on Accelyon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accelyon.

Explore the full profile